Komori
Financial Results Presentation2931Euglena Co.,Ltd.Food

Second-Quarter Financial Results Briefing for the Fiscal Year Ending December 2026

In the first half of the fiscal year ending December 2026, revenue and profit exceeded the year-earlier period, led primarily by the Healthcare business, and net income returned to profitability. In light of progress ahead of plan, only the full-year revenue forecast was raised from ¥52.0 billion to ¥53.0 billion, while all profit forecasts were left unchanged.

Worth reading
75Important
Scored from 5 of 6 sections
Direction
Improvement
Direction inferred from the company’s description.
Scale
1000
Millions of yen
Wording
Conditional
How definitive the wording is.

Contents of this document

Financial Results PresentationSecond quarter of the fiscal year ending December 20268 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales26,507 Millions of yen+8.0%
Operating profit1,871 Millions of yen+14.0%
Ordinary income1,709 Millions of yen+50.0%
Net income74 Millions of yen
Operating profit margin7.1 %
Full-year earnings forecast
Net Sales
53,000 Millions of yen
Adjusted EBITDA
7,000 Millions of yen
Operating profit
3,200 Millions of yen
Ordinary income
2,800 Millions of yen
Progress against full-year forecast　通期の予想に対して、いまどこまで進んだかの割合です。
Net Sales51%
Adjusted EBITDA54%
Operating profit58%
Ordinary income61%
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Progress exceeding plan
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
  • Biofuel priceUS$2.2-2.3/ℓ
  • Commercial plant production capacity in Malaysia725,000 KL/year
  • Our volume handled100,000 KL/year
  • Assumed price300 yen/L
New initiatives
  • Raised the full-year revenue forecast to ¥53.0 billion
  • The “Golden Euglena” business changed from 神鋼環境ソリューション to the Company
  • Made ヤマセ a subsidiary
  • Started joint research with Universiti Malaysia Sabah on functional materials for aquaculture
  • 丸紅エネルギー joined as a sales and supply partner for SUSTEO
Key KPIsA metric the company considers important as a management benchmark.
  • Number of subscription customers720,000 people
    Year on year against the same period last year+1%
  • Number of stores carrying Q'SAI products12,000 more than stores
  • Number of products certified under the Euglena-grown program10 over downloads
  • CKD comprehension accuracy rate91.3 %
    Year on year against the same period last yearUp from 34.6%
Unit price and quantity metricsThese figures show sales broken down by price and volume.
  • Number of subscription customers720,000 people
    Year on year against the same period last year+1%
  • Two-bottle subscription ratio (CONC)24 %
  • Two-bottle subscription ratio (Wrinkle Injection)9 %
Segment results
Healthcare
Net Sales
24,320 Millions of yen+7.0%
Adjusted EBITDA
4,646 Millions of yen+5.0%
Biofuels
Net Sales
764 Millions of yen+67.0%
Agribusiness
Net Sales
1,351 Millions of yen+10.0%
Adjusted EBITDA margin
10 %
Medium-term management plan targets
  • TargetAgri business revenue
    Target value10,000 Millions of yen
    Target fiscal year2,030 Millions of yen
  • TargetCKD-related business revenue
    Target value¥10,000 million-plus scale
    Target fiscal yearEarly 2030s
Market Size / Share
  • Number of CKD patients in Japan20,000,000 people
  • CKD-related medical expenses¥1.6 1 trillion or more
Contents of this document
ItemDetails
Document typeFinancial Results Presentation
Fiscal Period CoveredSecond quarter of the fiscal year ending December 2026
Net Sales26,507 Millions of yen (YoY +8.0%)
Operating profit1,871 Millions of yen (YoY +14.0%)
Ordinary income1,709 Millions of yen (YoY +50.0%)
Net income74 Millions of yen
Operating profit margin7.1 %
Full-year earnings forecastNet Sales 53,000 Millions of yen / Adjusted EBITDA 7,000 Millions of yen / Operating profit 3,200 Millions of yen / Ordinary income 2,800 Millions of yen / Net income Not disclosed
Progress against full-year forecastNet Sales 51% / Adjusted EBITDA 54% / Operating profit 58% / Ordinary income 61%
Self-assessment against the planProgress exceeding plan
Segment resultsHealthcare Net Sales 24,320 Millions of yen (YoY +7.0%) / Adjusted EBITDA 4,646 Millions of yen (YoY +5.0%) / Biofuels Net Sales 764 Millions of yen (YoY +67.0%) / Agribusiness Net Sales 1,351 Millions of yen (YoY +10.0%) / Adjusted EBITDA margin 10 %
Key KPIsIndicator name Number of subscription customers / Value 720,000 people / Year on year against the same period last year +1%, Indicator name Number of stores carrying Q'SAI products / Value 12,000 more than stores / Year on year against the same period last year Not disclosed, Indicator name Number of products certified under the Euglena-grown program / Value 10 over downloads / Year on year against the same period last year Not disclosed, Indicator name CKD comprehension accuracy rate / Value 91.3 % / Year on year against the same period last year Up from 34.6%
Unit price and quantity metricsIndicator name Number of subscription customers / Value 720,000 people / Year on year against the same period last year +1%, Indicator name Two-bottle subscription ratio (CONC) / Value 24 % / Year on year against the same period last year Not disclosed, Indicator name Two-bottle subscription ratio (Wrinkle Injection) / Value 9 % / Year on year against the same period last year Not disclosed
Assumptions Underlying the Business OutlookItem Biofuel price / Value US$2.2-2.3/ℓ, Item Commercial plant production capacity in Malaysia / Value 725,000 KL/year, Item Our volume handled / Value 100,000 KL/year, Item Assumed price / Value 300 yen/L
Medium-term management plan targetsTarget Agri business revenue / Target value 10,000 Millions of yen / Target fiscal year 2,030 Millions of yen, Target CKD-related business revenue / Target value ¥10,000 million-plus scale / Target fiscal year Early 2030s
Market Size / ShareItem Number of CKD patients in Japan / Value 20,000,000 people, Item CKD-related medical expenses / Value ¥1.6 1 trillion or more
New initiativesRaised the full-year revenue forecast to ¥53.0 billion, The “Golden Euglena” business changed from 神鋼環境ソリューション to the Company, Made ヤマセ a subsidiary, Started joint research with Universiti Malaysia Sabah on functional materials for aquaculture, 丸紅エネルギー joined as a sales and supply partner for SUSTEO
Items this document does not state (14)
Gross Profit MarginSelling, general and administrative expensesResults for the three months of the current quarterBreakdown of Factors Affecting the ChangeNumber of stores and locationsNumber of employeesRisk amount incorporated into the outlookFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Organic growth in the Healthcare business drove the increase in revenue, which progressed at a pace ahead of plan. Profit forecasts were left unchanged because the upside in profit is expected to be reallocated to growth investment aimed at medium- to long-term revenue growth.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Second-Quarter Financial Results Briefing for the Fiscal Year Ending December 2026 | Euglena Co.,Ltd. (2931) timely disclosure | Komori